Enzyme-free processes to produce hydrogels

WO2023193080A3PCT designated stage expired Publication Date: 2024-11-14TISSUELABS PESQUISA E DESENVOLVIMENTO LTDA
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/BR2023/050115
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-04-07
Filing Date
2023-04-06
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Existing methods for producing tissue-specific hydrogels involve enzymatic digestion, which can leave residual enzymes that are unsuitable for human application due to potential tissue degradation, limiting their use in transplants and regenerative therapies.

Method used

An enzyme-free process is developed to produce tissue-specific extracellular matrix solutions and hydrogels through decellularization and acidic hydrolysis without proteolytic enzymes, followed by neutralization and cross-linking, resulting in stronger and faster-crosslinking hydrogels suitable for human application.

Benefits of technology

The enzyme-free process generates hydrogels that are stronger and faster-crosslinking, reducing the risk of tissue rejection and enabling their use in human transplants and regenerative therapies with enhanced safety and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

The present invention pertains to the field of tissue and organ bioengineering and relates to an enzyme-free process to produce a tissue-specific extracellular matrix solution based on a decellularised extracellular matrix, comprising: (A) decellularising a tissue or organ in order to obtain an isolated extracellular matrix; and (b) hydrolising the isolated extracellular matrix in an acid environment, in the absence of proteolytic enzymes, optionally followed by purifying the solution. The present invention further relates to an enzyme-free process to produce a tissue-specific hydrogel. Thus, the present invention also relates to hydrogels produced by the present processes and to accessory inventions, wherein the tissue-specific extracellular matrix solution, the hydrogel and / or the products derived from the tissue-specific extracellular matrix solution form the core that interconnects the inventive aspects disclosed in the present document.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] ENZYME-FREE PROCESSES TO PRODUCE HYDROGELS

[0002] Field of invention

[0003] The present invention is in the field of tissue and organ bioengineering. Specifically, the present invention primarily relates to an enzyme-free process for obtaining a tissue-specific extracellular matrix solution, which is particularly useful for obtaining tissue-specific hydrogels and products derived from the tissue-specific extracellular matrix solution, which in turn are useful for tissue and organ reconstitution, such as for three-dimensional cell culture and its derivatives, such as bioprinting. Furthermore, the present invention relates to tissue-specific hydrogels and products derived from the tissue-specific extracellular matrix solution produced according to the present processes, which are free of proteolytic enzymes and are therefore suitable for human application, such as in tissue or organ transplantation.

[0004] The present invention also relates to accessory inventions, having the tissue-specific extracellular matrix solution, the tissue-specific hydrogel, and / or the products derived from the tissue-specific extracellular matrix solution as the core that connects the inventive aspects disclosed by this document.

[0005] Thus, the present invention also relates to a process for producing a tissue-specific soluble powder from the tissue-specific neutral extracellular matrix solution, the hydrogel or the product derived from the extracellular matrix solution of the present invention, and the tissue-specific soluble powder; to a process for producing a tissue-specific membrane from the tissue-specific neutral extracellular matrix solution, the hydrogel or the product derived from the extracellular matrix solution of the present invention, and the tissue-specific membrane; to a process for providing bioactive compounds for regenerating tissue using the tissue-specific neutral extracellular matrix solution, the hydrogel or the product derived from the extracellular matrix solution of the present invention; to a process for providing bioactive compounds for regenerating tissue using the tissue-specific membrane of the present invention;to an in vitro process for delivering bioactive compounds via the hydrogel or via the extracellular matrix solution-derived product of the present invention; to the use of the tissue-specific extracellular matrix solution, the hydrogel, or the extracellular matrix solution-derived product of the present invention for the manufacture of a product; to other uses of the tissue-specific extracellular matrix solution, the hydrogel, or the extracellular matrix solution-derived product of the present invention; to an additive ingredient for cell culture medium comprising the tissue-specific soluble powder of the present invention; to a process for culturing cells within the hydrogel or the extracellular matrix solution-derived product of the present invention; to a process for culturing cell aggregates within the hydrogel or the extracellular matrix solution-derived product of the present invention;to a process for bioprinting 3D bioinks comprising cells or cell aggregates within the tissue-specific neutral extracellular matrix solution, the hydrogel or the product derived from the extracellular matrix solution of the present invention; to a process for 3D bioprinting from the tissue-specific extracellular matrix solution produced by the enzyme-free process to produce said solution of the present invention; and to a kit comprising the tissue-specific extracellular matrix solution produced by the enzyme-free process to produce said solution of the present invention, the tissue-specific soluble powder or product derived from the tissue-specific extracellular matrix solution of the present invention.;

[0006] Background of the invention

[0007] Current hydrogels are mostly tissue-specific (or organ-specific) hydrogels. Simply put, the extracellular matrix, composed of proteins that support the cells, is obtained from animal organs such as the liver, kidney, heart, etc., through a process of cell extraction or decellularization. This extracellular matrix is ​​used to produce hydrogels, which are then used to reconstruct tissues or organs, such as for three-dimensional (3D) cell culture and its derivatives, such as 3D bioprinting, with potential application in transplantation.

[0008] Many state-of-the-art hydrogel production processes involve enzymatic digestion of extracellular matrix proteins. However, in these processes, these enzymes may remain present in the final products, making them unsuitable for human use, given the potential for enzyme reactivation in the human body, resulting in undesirable tissue proteolysis.

[0009] Thus, as a solution to this prior art problem, the present invention relates to a process for producing a tissue-specific extracellular matrix solution useful for obtaining hydrogels and products derived from said solution, without the need for proteolytic enzymes. The products generated from said solution can be applied to humans, such as tissue or organ transplants. Furthermore, they may have other applications and produce other products, such as those disclosed in this document, as well as the processes for obtaining them.

[0010] Some prior art documents, such as document PI 0800603-2 and BR 10 2014 030834 2, refer to methods of decellularization of the extracellular matrix for the manufacture of solid matrices (not gels) to be used as prostheses or biological grafts, with or without cells, aiming at the therapeutic application of decellularized tissues.

[0011] Other documents, such as BR 11 2012 028265 4 and BR 1 1 2014 026090 7, describe the use of biomaterials containing, but not manufactured from, decellularized extracellular matrix for therapeutic application in several areas.

[0012] Document PI 1012502-7 describes the process of obtaining pure type I collagen from decellularized extracellular matrix for therapeutic application in dermal lesions or in conjunction with bone ceramic and / or hydroxyapatite for the manufacture of bone implants.

[0013] None of these documents describe the manufacture of tissue-specific solutions, products, or hydrogels obtained through enzyme-free processes derived from decellularized extracellular matrix for three-dimensional cell culture or its derivatives, such as bioprinting. It is no coincidence that the processes described therein differ substantially from those disclosed by the present invention. Some documents describe, in a generic way, the method of production of hydrogels derived from decellularized extracellular matrix, such as US-8691276-B2, CN-104971380-B, CN-104225667-B and CN- 105169483-B, while others describe the manufacture of hydrogels derived from decellularized extracellular matrix from specific organs, such as US-7919121-B2 and KR-101637548-B1 (liver), EP-2349292-B1 (heart), US-9277999-B2 and US-9861662-B2 (osteocartilaginous tissues), US-8637067-B1 (blood vessels), US-10016464-B2 (amniotic membrane), US-9737635-B2 (nerve tissue) and CN- 104307046-B (bone marrow).

[0014] Other documents describe the application of these hydrogels, alone or in combination with other compounds, in regenerative therapies, that is, for tissue repair in therapeutic applications, such as EP-2162142-B1, US-10092676-B2, US-9789224-B2 and US-9592256-B2.

[0015] Furthermore, some documents describe the processing of the extracellular matrix for use in different applications and, among the processing methods described, include the production of hydrogels based on extracellular matrix, such as US-9788821-B2, US-8187619-B2 and US-9938502-B2.

[0016] However, none of these documents discloses or suggests an enzyme-free process for producing an extracellular matrix solution useful for the production of products such as tissue-specific hydrogels based on decellularized extracellular matrices, as disclosed by the present invention, nor their products and uses. Therefore, they lack the potential for therapeutic use, with a lower risk of rejection, and / or as an experimental or clinical tool due to the release of factors useful for tissue regeneration, among others. Furthermore, prior art processes have disadvantages, which are addressed by the present invention. Prior art enzymatic methods generate weaker, slow-crosslinking hydrogels, while the enzyme-free method of the present invention generates stronger, fast-crosslinking hydrogels.

[0017] Likewise, the prior art documents, because they did not reveal or suggest the products, processes and uses of the present invention, could not have anticipated or suggested the other embodiments as revealed herein.

[0018] Brief description of the invention

[0019] The object of the present invention is therefore an enzyme-free process for producing a tissue-specific extracellular matrix solution, based on decellularized extracellular matrix, comprising:

[0020] (a) decellularize a tissue or organ to obtain isolated extracellular matrix; and

[0021] (b) hydrolyze the isolated extracellular matrix in an acidic environment in the absence of proteolytic enzymes, optionally followed by purification of the solution.

[0022] In a preferred embodiment of the process of the present invention, after step (b), step (c) is carried out to neutralize the pH of the hydrolyzed extracellular matrix solution from step (b) to obtain a tissue-specific neutral extracellular matrix solution. In another preferred embodiment of the process of the present invention, after step (c), step (d) is carried out to crosslink the tissue-specific neutral extracellular matrix solution for transition to a hydrogel.

[0023] A second object of the present invention relates to an enzyme-free process for producing a tissue-specific hydrogel, based on decellularized extracellular matrix, comprising: producing a tissue-specific extracellular matrix solution by means of steps (a) and (b) of the enzyme-free process for producing said solution of the present invention;

[0024] (c) neutralizing the pH of the hydrolyzed tissue-specific extracellular matrix solution from step (b) to obtain a neutral tissue-specific extracellular matrix solution; and

[0025] (d) crosslink the tissue-specific neutral extracellular matrix solution for transition to a hydrogel.

[0026] In a preferred embodiment of this and the process, first object of the present invention, between steps (a) and (b), the step of lyophilizing the isolated extracellular matrix and pulverizing the lyophilized material is carried out to obtain a fine powder of isolated cellular matrix.

[0027] In another preferred embodiment of the processes of the present invention, between steps (c) and (d), the steps of lyophilizing the hydrolyzed extracellular matrix solution are carried out, resolubilizing it with an aqueous solution, with the pH being able to be adjusted or not; preferably, the resolubilization is with an acidic solution, followed by neutralization and balancing of the salts.

[0028] In yet another preferred embodiment of the processes of the present invention, the decellularization is carried out with at least one detergent selected from the group consisting of Triton X-100, sodium dodecyl sulfate (SDS), sodium lauryl ether sulfate (SLES), sodium cholate, sodium deoxycholate, Sulfobetaine-10 (SB-10), Sulfobetaine-16 (SB-16), Triton X-200, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS), sodium lauroyl sarcosinate (sarkosyl), n-dodecyl-BD-maltoside (DDM), digitonin, polysorbate 20 and polysorbate 80.

[0029] In yet another preferred embodiment of the processes of the present invention, hydrolysis in an acidic environment is carried out with an acid selected from the group consisting of acetic acid, hydrochloric acid, citric acid, lactic acid and trifluoroacetic acid, preferably acetic acid or hydrochloric acid, more preferably acetic acid.

[0030] In yet another preferred embodiment of the processes of the present invention, the neutralization is by dialysis or carried out with a basic solution, preferably a solution comprising sodium hydroxide and / or sodium bicarbonate, optionally together with a buffer solution comprising one or more of sodium bicarbonate buffer, phosphate-buffered saline, Dulbecco's phosphate-buffered saline, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid) and MOPS (3-(N-morpholino)propanesulfonic acid).

[0031] In yet another preferred embodiment of the methods of the present invention, the tissue or organ of origin is selected from the group consisting of adipose tissue, bone tissue, brain, cartilage tissue, colon, kidney, liver, lung, muscle tissue, myocardial tissue, pancreas, skin, spleen, stomach, vascular tissue, dental tissue, glandular tissue such as the adrenal gland, parathyroid gland, thyroid gland, pituitary gland and salivary gland, bone marrow tissue, male reproductive system tissue such as the testis, epididymis, prostate, seminal vesicle and vas deferens, female reproductive system tissue such as the vagina, cervix, endometrium, fallopian tube, ovary and placenta, intestine, urinary bladder and eye.

[0032] A third object of the present invention relates to a tissue-specific hydrogel produced by the enzyme-free processes defined herein. In the case of the process, the first object of the present invention, in particular, the hydrogel is obtained after crosslinking.

[0033] A fourth object of the present invention relates to a process for producing a product derived from the tissue-specific extracellular matrix solution, comprising subjecting the tissue-specific extracellular matrix solution produced by the enzyme-free process defined in this document, to one or more of the following chemical modifications:

[0034] (i) introduce acrylate derivatives (such as methacrylate);

[0035] (ii) introduce alkenes, for thiol-ene chemistry (such as thiol-norbornene);

[0036] (iii) introduce thiols, for thiol-ene chemistry or intermolecular disulfide bridges; and / or

[0037] (iv) introduce other chemical groups for bio-orthogonal reactions (such as aldehyde and hydrazide).

[0038] In a preferred embodiment of the process of the present invention, the process further comprises crosslinking the modified tissue-specific extracellular matrix solution for transition to a hydrogel.

[0039] A fifth object of the present invention relates to a product derived from the tissue-specific extracellular matrix solution, in which the product is the tissue-specific solution produced by the enzyme-free process defined in this document, or the tissue-specific hydrogel obtained from the same, defined in this document, or produced by the enzyme-free processes defined in this document, comprising one or more of the following chemical modifications:

[0040] (i) addition of acrylate derivatives (such as methacrylation);

[0041] (ii) addition of alkenes for thiol-ene chemistry (such as thiol-norbornene);

[0042] (iii) addition of thiols for thiol-ene chemistry or intermolecular disulfide bridges; and / or

[0043] (iv) addition of other chemical groups for bio-orthogonal reactions (such as aldehyde and hydrazide).

[0044] A sixth object of the present invention relates to a process for producing a tissue-specific soluble powder, comprising subjecting the tissue-specific neutral extracellular matrix solution, produced by the enzyme-free process defined herein, or the hydrogel defined herein, or produced by the enzyme-free processes defined herein, or the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, to lyophilization and pulverization.

[0045] A seventh object of the present invention relates to a tissue-specific soluble powder obtained by lyophilizing and spraying the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined herein, or the tissue-specific hydrogel defined herein, or produced by the enzyme-free processes defined herein, or the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein.

[0046] An eighth object of the present invention relates to a process for producing a tissue-specific membrane, comprising subjecting the tissue-specific neutral extracellular matrix solution, produced by the enzyme-free process defined herein, or the hydrogel defined herein, or produced by the enzyme-free processes defined herein, or the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, to dehydration.

[0047] A ninth object of the present invention relates to a tissue-specific membrane obtained by dehydrating the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined herein, or the hydrogel defined herein, or produced by the enzyme-free processes defined herein, or the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein.

[0048] A tenth object of the present invention relates to a process for providing bioactive compounds for regenerating tissue using the tissue-specific neutral extracellular matrix solution, produced by the enzyme-free process for producing said solution defined herein, the hydrogel defined herein, or produced by the enzyme-free processes defined herein, or the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, comprising:

[0049] (a) loading the solution, the tissue-specific hydrogel or the product derived from the tissue-specific extracellular matrix solution with the bioactive compound(s); and

[0050] (b) applying the solution, hydrogel or extracellular matrix solution-derived product loaded with the bioactive compound(s) onto or into the target tissue to be regenerated.

[0051] An eleventh object of the present invention relates to a process for providing bioactive compounds for regenerating tissue using the tissue-specific membrane defined herein, or produced by the process for producing a tissue-specific membrane defined herein, comprising: (a) loading the tissue-specific neutral extracellular matrix solution, the tissue-specific hydrogel or the product derived from the tissue-specific extracellular matrix solution with the bioactive compound(s);

[0052] (b) dehydrating the solution, hydrogel or extracellular matrix solution-derived product loaded with the bioactive compound(s) to produce a membrane; and

[0053] (c) apply the membrane loaded with the bioactive compound(s) to the target tissue to be regenerated; in which steps (a) and (b) may occur in any order.

[0054] A twelfth object of the present invention relates to an in vitro process for delivering bioactive compounds by means of the tissue-specific hydrogel defined herein, or produced by the enzyme-free processes defined herein, in the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, wherein the hydrogel or the product derived from the extracellular matrix solution is for tissue regeneration, comprising loading the tissue-specific hydrogel or the product derived from the tissue-specific extracellular matrix solution with the bioactive compound(s).

[0055] In a preferred embodiment of the process of the present invention, the process further comprises dehydrating the hydrogel or the product derived from the extracellular matrix solution loaded with the bioactive compound(s) to produce a membrane.

[0056] In another preferred embodiment of this and other processes of the present invention, the bioactive compound(s) is / are selected from the group consisting of:

[0057] - cells, preferably differentiated adult cells and stem cells; preferably wherein the differentiated adult cells are cells derived primarily from endoderm, cells derived primarily from ectoderm, and cells derived primarily from mesoderm; and preferably wherein the stem cells are embryonic stem cells, induced pluripotent stem cells, and adult stem cells, or any combination thereof;

[0058] - factors secreted by cells, preferably selected from the group consisting of growth factors, cytokines, chemokines and micro-RNAs, or any combinations thereof;

[0059] - vesicles secreted by cells, preferably selected from the group consisting of exosomes, microvesicles, apoptotic bodies and ectosomes, or any combinations thereof;

[0060] - nucleic acids, preferably selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNAs (rRNA), microRNAs (miRNA), small interfering RNAs (siRNA), piwi-interacting RNAs (piRNA), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNA), extracellular RNAs (exRNA), small Cajal body-specific RNAs (scaRNA), long non-coding RNAs (lncRNA), double-stranded RNAs (dsRNA) and circular RNAs, or any combinations thereof;

[0061] - medicines;

[0062] - biological medical products, preferably selected from the group consisting of chimeric antigen receptor T cells (CAR T cells), monoclonal antibodies, fusion proteins, tumor necrosis factor alpha (TNFa), leukocyte surface glycoproteins, adhesion molecules, immunoglobulins, receptor targets and viruses, or any combinations thereof;

[0063] - metallic particles (such as silver nanoparticles), ceramic particles (such as hydroxyapatite), organic particles (such as nanoemulsions and polymeric nanoparticles), lipid particles (such as liposomes) and carbon nanomaterials (such as fullerenes, carbon nanotubes, graphene and graphene oxide), or any combinations thereof; or any combinations thereof.

[0064] A thirteenth object of the present invention relates to the use of the tissue-specific neutral extracellular matrix solution, produced by the process defined herein, or of the tissue-specific hydrogel defined herein, or produced by the enzyme-free processes defined herein, or of the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, for the manufacture of a product.

[0065] In a preferred embodiment of the use of the present invention, the product is for regenerating tissue, and in which the tissue-specific neutral extracellular matrix solution, the tissue-specific hydrogel or the product derived from the tissue-specific extracellular matrix solution is loaded with one or more bioactive compounds, in which the one or more bioactive compounds are selected from the group consisting of cells, cell-secreted factors, cell-secreted vesicles, nucleic acids, drugs, biological medical products, metal particles (such as silver nanoparticles), ceramic particles (such as hydroxyapatite), organic particles (such as nanoemulsions and polymeric nanoparticles), lipid particles (such as liposomes) and carbon nanomaterials (such as fullerenes, carbon nanotubes, graphene and graphene oxide), or a combination thereof.

[0066] In another preferred embodiment of the use of the present invention, the product is selected from the group consisting of a tissue-specific soluble powder, a tissue-specific membrane, a loading support for bioactive compounds, such as for tissue regeneration, an additive ingredient for cell culture medium, a bioink for 3D bioprinting and a surface coating solution for cell culture.

[0067] A fourteenth object of the present invention relates to the use of the tissue-specific neutral extracellular matrix solution produced by the process defined herein, or of the hydrogel defined herein, or produced by the enzyme-free processes defined herein, or of the product derived from the tissue-specific extracellular matrix solution defined herein, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution defined herein, as a tissue-specific soluble powder, as a tissue-specific membrane, as a loading support for bioactive compounds, such as for regenerating tissue and cultivating cells and / or cell aggregates, as an additive ingredient for cell culture medium, as a bioink for 3D bioprinting, and as a surface coating solution for cell culture.A fifteenth object of the present invention relates to the use of the tissue-specific extracellular matrix solution, produced by the process defined in this document, for the manufacture of derived products, in which the products comprise the solution with one or more of the following chemical modifications:

[0068] (i) addition of acrylate derivatives (such as methacrylation);

[0069] (ii) addition of alkenes for thiol-ene chemistry (such as thiol-norbornene);

[0070] (iii) addition of thiols for thiol-ene chemistry or intermolecular disulfide bridges; and / or

[0071] (iv) addition of other chemical groups for bio-orthogonal reactions (such as aldehyde and hydrazide).

[0072] A sixteenth object of the present invention relates to an additive ingredient for cell culture medium, comprising the tissue-specific soluble powder defined in this document.

[0073] A seventeenth object of the present invention relates to a process for cultivating cells within the hydrogel defined herein, or produced by the enzyme-free processes defined herein, or the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, wherein the process comprises:

[0074] (a) loading the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined in this tissue-specific document or the product derived from the tissue-specific extracellular matrix solution with the cells, at a cell concentration between 1 x 10 3 and 1 x 10 10 cells / mL;

[0075] (b) crosslinking the tissue-specific neutral extracellular matrix solution or the tissue-specific extracellular matrix solution-derived product with the cells to produce a crosslinked 3D construct; and

[0076] (c) provide the cells with growth conditions that allow them to populate the 3D cross-linked construct to form a mature functional tissue.

[0077] An eighteenth object of the present invention relates to a process for cultivating cell aggregates within the hydrogel defined herein, or produced by the enzyme-free processes defined herein, or the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, wherein the process comprises:

[0078] (a) loading the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined herein or the product derived from the tissue-specific extracellular matrix solution with the cell aggregates, such as spheroids, organoids and cell monolayers;

[0079] (b) crosslinking the tissue-specific neutral extracellular matrix solution or the tissue-specific extracellular matrix solution-derived product with the cell aggregates to produce a crosslinked 3D construct; and

[0080] (c) provide cell aggregates with conditions for growth or maintenance.

[0081] A nineteenth object of the present invention relates to a process for bioprinting 3D bioinks, comprising cells or cell aggregates within the tissue-specific hydrogel defined herein, or produced by the enzyme-free processes defined herein, or of the product derived from the extracellular matrix solution defined herein, or produced by the process for producing a product derived from the extracellular matrix solution defined herein, or of the tissue-specific extracellular matrix solution, produced by the enzyme-free process for producing a tissue-specific extracellular matrix solution defined herein, wherein the process comprises:

[0082] (a) loading cells or cell aggregates into the tissue-specific hydrogel or the product derived from the tissue-specific extracellular matrix solution or the tissue-specific neutral extracellular matrix solution, or into combinations of such hydrogels or products or solutions with other biomaterials;

[0083] (b) load the mixture described in item (a) into the printing chamber of a 3D bioprinter;

[0084] (c) perform the 3D printing steps, according to the mechanism of action of the 3D bioprinter;

[0085] (d) cross-linking to stabilize the 3D bioprinted construct; and

[0086] (e) provide the cells with growth conditions to allow them to populate the 3D bioprinted construct to form a mature functional tissue.

[0087] A twentieth object of the present invention relates to a process for 3D bioprinting, from a tissue-specific extracellular matrix solution, comprising: producing a tissue-specific extracellular matrix solution by means of steps (a) and (b) of the enzyme-free process for producing said solution as defined in this document;

[0088] (c) loading the hydrolyzed extracellular matrix solution from step (b) into the printing chamber of a 3D bioprinter;

[0089] (d) perform the 3D printing steps, according to the mechanism of action of the 3D bioprinter; and

[0090] (e) cross-linking to stabilize the 3D bioprinted construct.

[0091] In a preferred embodiment of the 3D bioprinting process of the present invention, between steps (b) and (c), the step of neutralizing the pH of the hydrolyzed extracellular matrix solution of step (b) is carried out to obtain a tissue-specific neutral extracellular matrix solution.

[0092] In another preferred embodiment of the 3D bioprinting process of the present invention, the pH neutralization step of the hydrolyzed extracellular matrix solution is carried out during or after the bioprinting of step (d) or after the crosslinking to stabilize the bioprinted 3D construction of step (e).

[0093] In yet another preferred embodiment of the 3D bioprinting processes of the present invention, between steps (b) and (c), the step of incorporating biomaterials and / or bioactive compounds is carried out.

[0094] In yet another preferred embodiment of the 3D bioprinting methods of the present invention, the printing chamber of the 3D bioprinter comprises a syringe, a Petri dish, a vial, or another 3D bioprinting chamber. In yet another preferred embodiment of the 3D bioprinting methods of the present invention, the 3D bioprinter is an extrusion-based bioprinter, a stereolithography-based bioprinter, an inkjet-based bioprinter, a laser-based bioprinter, a tomography-based bioprinter, an acoustic-based bioprinter, or an electrospinning-based bioprinter.

[0095] In yet another preferred embodiment of the 3D bioprinting processes of the present invention, as well as other processes of the present invention, where relevant, the crosslinking preferably comprises one or more of physical crosslinking, such as by changing temperature and / or pH, and adding ions to promote ionic interaction; chemical crosslinking, such as reaction to obtain covalent bonds, such as by exposure to light, such as visible light, ultraviolet light and infrared light.

[0096] A twenty-first object of the present invention relates to a kit, comprising the tissue-specific extracellular matrix solution produced by the enzyme-free process for producing said solution defined herein, or the tissue-specific soluble powder defined herein, or produced by the process for producing said powder defined herein, or product derived from the tissue-specific extracellular matrix solution defined herein, or produced by the process for producing said product defined herein.

[0097] It is worth noting that any of the objects or their preferred realizations described above can serve as a basis for composing the other objects and their preferred realizations, even if such relationship(s) has not been explicitly described.

[0098] Detailed description of the invention

[0099] Throughout this document, unless otherwise indicated, the limits of a value range are included within that range. Furthermore, value ranges include all numbers and fractions within the respective ranges.

[0100] Throughout this document, the singular forms “um”, “uma” and “o / a” include both the singular and the corresponding plurals, and vice versa, unless the context clearly dictates otherwise.

[0101] Throughout this document, the expression "at least one" is equivalent to the expression "one or more", and means one or more members, or at least one member of a group of members. These terms include any one of > 1, > 2, > 3, > 4, > 5, > 6, > 7, etc. of said members, up to all said members.

[0102] Throughout this document, the terms “about” or “approximately,” when referring to a measurable value such as a parameter, a quantity, a temporary duration, and the like, mean variations from the specified value, such as variations of + / - 10% or less, preferably + / - 5% or less, more preferably + / - 1% or less, and even more preferably + / - 0.1% or less, to the extent that such variations are reasonably appropriate for each applicable parameter of the invention. It is understood that the value to which the modifier “about” refers is also specifically and preferably disclosed.

[0103] Throughout this document, words and expressions such as “preferably”, “particularly”, “for example”, “as”, “such as”, “more particularly”, “most preferably” and similar, and their variations, should be interpreted as entirely optional characteristics, preferred realizations or possible non-exhaustive examples, without conferring a limiting nature of scope.

[0104] Throughout this document, the word "comprise" and any variations such as "comprise" or "comprise" should be interpreted as "open-ended terms," ​​which may imply the inclusion of additional elements or groups of elements not explicitly described, and are not limitative. Likewise, the words "including" and "encompassing" and any variations thereof.

[0105] Throughout this document, the word “consists”, and any variations such as “consist” or “consisting”, must be interpreted as “closed terms”, and cannot imply the inclusion of additional elements or groups of elements, which have not been explicitly described, having a limiting nature.

[0106] Unless otherwise explicitly stated, all acronyms, expressions, and / or technical terms should be interpreted as having the meanings generally used and widely known in the technical field of the present invention. In some cases, terms with commonly understood meanings are defined in this document for clarity and / or ready reference, and the inclusion of such definitions in this document should not necessarily be construed as representing a substantial departure from what is generally understood in the prior art.

[0107] Unless otherwise explicitly stated, the techniques and procedures described in or referred to herein are generally well understood and employed using conventional methodology, based on available literature and the knowledge of one skilled in the art.

[0108] Throughout this document, all headings and subheadings are used for convenience only and should not be construed as limitations of this invention.

[0109] Throughout this document, all cited references, books, articles, patent documents and the like shall be construed as incorporated by reference.

[0110] Throughout this document, the expression “tissue-specific” should be interpreted as including the expression “organ-specific”, and vice versa, so that it encompasses any and all tissues or organs, regardless of the expression used.According to the present invention, preferred tissues or organs of origin for the production of tissue- or organ-specific hydrogels belong to any relevant animal species or the human being, and are selected from the group consisting of adipose tissue, bone tissue, brain, cartilage tissue, colon, kidney, liver, lung, muscle tissue, myocardial tissue, pancreas, skin, spleen, stomach, vascular tissue, dental tissue, glandular tissue such as the adrenal gland, parathyroid gland, thyroid gland, pituitary gland and salivary gland, bone marrow tissue, male reproductive system tissue such as the testis, epididymis, prostate, seminal vesicle and vas deferens, female reproductive system tissue such as the vagina, cervix, endometrium, fallopian tube, ovary and placenta, intestine, urinary bladder and eye.

[0111] Throughout this document, the term “bioactive compound” is broad and should be interpreted as encompassing any compound, component, or active ingredient that exerts an effect on a living organism, tissue, organ, or cell. Preferably, the bioactive compound (or component, or active ingredient) is selected from the group consisting of cells (such as stem cells, such as embryonic stem cells, induced pluripotent stem cells, adult stem cells, cells derived primarily from endoderm, cells derived primarily from ectoderm, and cells derived primarily from mesoderm, or a combination thereof); cell-secreted factors (such as growth factors, cytokines, chemokines, and microRNAs, or a combination thereof); cell-secreted vesicles (such as exosomes, microvesicles, apoptotic bodies, and ectosomes, or a combination thereof);nucleic acids (deoxyribonucleic acid (DNA), ribonucleic acid (RNA), messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNAs (rRNA), microRNAs (miRNA), small interfering RNAs (siRNA), Piwi-interacting RNAs (piRNA), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNA), extracellular RNAs (exRNA), Cajal body-specific small RNAs (scaRNA), long non-coding RNAs (lncRNAs), double-stranded RNAs (dsRNAs), and circular RNAs, or a combination thereof); medications;biological medical products (such as chimeric antigen receptor T cells (CAR T cells), monoclonal antibodies, fusion proteins, tumor necrosis factor-α (TNFa), leukocyte surface glycoproteins, adhesion molecules, immunoglobulins, receptor targets and viruses, or a combination thereof), metal particles (such as silver nanoparticles), ceramic particles (such as hydroxyapatite), organic particles (such as nanoemulsions and polymeric nanoparticles), lipid particles (such as liposomes), and carbon nanomaterials (such as fullerenes, carbon nanotubes, graphene, and graphene oxide); or a combination thereof.;

[0112] Throughout this document, the expression “regenerate tissue” refers to both the regeneration, which can be total or partial (repair), of tissues and organs, and the terms “regenerate”, “regeneration” and their variations, in this context, refer to the ability to bring damaged or imperfect tissue to normal or improved conditions, in vivo or in vitro.

[0113] Throughout this document, the terms "crosslinking," "reticulate," and any variations thereof should be interpreted as encompassing any crosslinking techniques known in the art of the field of the present invention, preferably comprising one or more of physical crosslinking, such as by changing temperature (including increasing or decreasing temperature, including freezing) and / or pH, and adding ions to promote ionic interaction; and chemical crosslinking, such as a reaction to obtain covalent bonds, such as by exposure to light, such as visible light, ultraviolet light, and infrared light. Preferably, crosslinking is by changing temperature, and can be performed by several known techniques, such as through the use of an incubator. Parameters such as exposure time at a given temperature can vary and be adjusted by a person skilled in the art, without incurring undue experimentation, depending on the tissue in question.Usually, the temperature for transition of the extracellular matrix solution to a hydrogel is from about 4°C to about 50°C. Preferably, the temperature is from about 15°C to about 45°C; more preferably, it is from about 20°C to about 40°C; even more preferably, it is from about 25°C to about 38.5°C; still more preferably, it is from about 37°C. Usually, using an incubator with temperature control, relative humidity of 95% and CO2 level of 5%, the time is from about 15 minutes to about 2 hours, preferably about 1 hour, at a temperature of 37°C.

[0114] The present invention relates to an enzyme-free process for producing a tissue-specific extracellular matrix solution based on decellularized extracellular matrix, comprising:

[0115] (a) decellularize a tissue or organ to obtain isolated extracellular matrix; and

[0116] (b) hydrolyze the isolated extracellular matrix in an acidic environment in the absence of proteolytic enzymes, optionally followed by purification of the solution.

[0117] In a preferred embodiment of the process of the present invention, after step (b), step (c) is carried out to neutralize the pH of the hydrolyzed extracellular matrix solution from step (b) to obtain a tissue-specific neutral extracellular matrix solution.

[0118] Note that, optionally, after hydrolysis, and before neutralization, when present, it may be of interest to proceed with purification of the solution. Purification, even when not specifically indicated, may be present in any of the processes disclosed herein that include these steps, and may be carried out by any technique known in the art of the field of the present invention for the removal of impurities. Preferred techniques include centrifugation and / or filtration. Centrifugation may preferably occur at about 1,000 g to about 100,000 g, preferably at about 15,000 g to about 90,000 g, for about 1 minute to about 1 hour, preferably for at least about 15 minutes to about 45 minutes; and filtration through membranes, such as through membranes with pore sizes preferably ranging from 0.22 μm to 70 μm, more preferably between 1 μm and 10 μm.

[0119] To obtain a tissue-specific hydrogel according to the process of the present invention, after step (c), step (d) is carried out to crosslink the tissue-specific neutral extracellular matrix solution for transition to a hydrogel.

[0120] The present invention also relates to an enzyme-free process for producing a tissue-specific hydrogel based on decellularized extracellular matrix, comprising producing a tissue-specific extracellular matrix solution by means of steps (a) and (b) of the enzyme-free process of the present invention for producing said solution;

[0121] (c) neutralizing the pH of the hydrolyzed tissue-specific extracellular matrix solution from step (b) to obtain a neutral tissue-specific extracellular matrix solution; and

[0122] (d) crosslink the tissue-specific neutral extracellular matrix solution for transition to a hydrogel.

[0123] Likewise, optionally, after hydrolysis and before neutralization, it may be of interest to proceed with purification of the solution, as previously described herein.

[0124] It may be advantageous, as an optional step of the enzyme-free process for producing the tissue-specific extracellular matrix solution, as well as for producing the tissue-specific hydrogels of the present invention, between steps (a) and (b), to proceed with the step of lyophilizing the isolated extracellular matrix and pulverizing the lyophilized material to obtain a fine powder of isolated extracellular matrix, which makes the hydrolysis of step (b), as well as the process as a whole, faster.

[0125] Optionally, in the case of the enzyme-free processes of the present invention for the production of a tissue-specific hydrogel, the steps (c) and (d) are followed by the lyophilization step of the hydrolyzed extracellular matrix solution, followed by the steps of resolubilization with an aqueous solution, the pH of which may or may not be adjusted, preferably to about 7 to about 7.4; preferably, the resolubilization is with an acidic solution, followed by neutralization to said preferred pH, and salt balance.

[0126] According to the present invention, any prior art decellularization technique for a tissue or organ to obtain the isolated extracellular matrix can be employed. Many decellularization processes are described in the prior art, such as mechanical disruption, freeze-thaw cycles, treatment with osmotic, hyposmotic, and hyperosmotic solutions, treatment with enzymes, and treatment with alcohols, acids, bases, and detergents, among others.Preferably, the decellularization of the tissue or organ to obtain the isolated extracellular matrix is ​​carried out by treatments with detergents, such as with Triton X-100, sodium dodecyl sulfate (SDS), sodium lauryl ether sulfate (SLES), sodium cholate, sodium deoxycholate, Sulfobetaine-10 (SB-10), Sulfobetaine-16 (SB-16), Triton X-200, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS), sodium lauroyl sarcosinate (sarkosyl), n-dodecyl-BD-maltoside (DDM), digitonin, polysorbate 20 and polysorbate 80. Preferred detergents according to the present invention are Triton X-100, sodium dodecyl sulfate (SDS), sodium lauryl ether sulfate (SLES), sodium deoxycholate, ... X-200 and 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS). Even more preferably, the detergents are Triton X-100, sodium dodecyl sulfate (SDS), and sodium lauryl ether sulfate (SLES).

[0127] Preferably, the decellularization protocol includes dissection of the native tissue; freeze / thaw cycles of the native tissue; grinding of the native tissue; followed by water washes; incubation with deionized water; incubation with water saturated with sodium chloride; incubation with sodium lauryl ether sulfate (SLES) or sodium dodecyl sulfate (SDS) at 0.1% to 2% for 12 to 48 h, preferably at 1% for 24 hours; water washes; incubation with Triton X-100 at 0.1% to 2% for 12 to 48 h, preferably at 1% for 24 hours; and water washes. The skilled artisan will readily recognize variations of the described protocol to properly obtain decellularization of the target tissue by the described method, the number of washes, freeze / thaw cycles, among other steps, not being of particular relevance to the present invention.

[0128] Likewise, in any case according to the present invention, any freeze-drying technique described in the prior art may be employed. Typical freeze-drying techniques generally employ a freeze-dryer, according to the standard methodology of each equipment. Any equipment may be used in the context of the present invention.

[0129] Likewise, any technique for pulverizing the freeze-dried material to obtain a fine powder, as described in the prior art, may be employed. Typical pulverizing techniques include equipment for this purpose, such as a mill (impact mill, cutting mill (knife mill), among others). Preferably, lyophilization is at -65°C to -35°C for 12 to 48 hours, preferably at -45°C for 24 hours, followed by pulverization in a Willey-type knife mill.

[0130] The hydrolysis of the isolated extracellular matrix, whether or not it has been lyophilized and pulverized (therefore, whether or not it is in the form of a fine extracellular matrix powder), according to the present invention, must be carried out in an acidic environment and in the absence of any proteolytic enzymes, generally at 1 to 100 mg / mL of lyophilized extracellular matrix powder, preferably 5 to 20 mg / mL and even more preferably at 10 mg / mL of lyophilized extracellular matrix powder. Usual acid hydrolysis techniques include the use of an organic or inorganic acid, which may be a weak acid or a strong acid, such as acetic acid, hydrochloric acid, citric acid, lactic acid and trifluoroacetic acid. The acid concentration may vary depending on the acid in question, and may be from 0.001 M to 2 M. Preferably, hydrolysis in an acidic environment is carried out with acetic acid or hydrochloric acid, preferably acetic acid, preferably 0.5 M acetic acid.Hydrolysis time can vary depending on the tissue in question, ranging from a few hours to a few days, or even weeks. It may be advantageous to keep the hydrolysis under agitation at a cool temperature, such as in a refrigerator at around 4°C. A specialist in the field would know how to make small improvements to this step and its variables, depending on the acid and the tissue in question.

[0131] The neutralization of the pH of the hydrolyzed extracellular matrix solution from the previous step to obtain a tissue-specific neutral extracellular matrix solution can be accomplished by any technique commonly employed for this purpose. Known techniques include the use of a basic solution, preferably a solution comprising sodium hydroxide and / or sodium bicarbonate. Optionally, when salt balance is required, a buffer solution comprising one or more of sodium bicarbonate buffer, phosphate-buffered saline, Dulbecco's phosphate-buffered saline, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), and MOPS (3-(N-morpholino)propanesulfonic acid) can be used together with the basic solution, by mixing the basic solution with the buffer solution and with the hydrolyzed extracellular matrix.In general, the basic solution, with or without buffer(s), acts immediately to neutralize the acid, and incubation for a few minutes to several hours is also possible. The quantities of reagents and other conditions can be adjusted depending on the acid in question, for example, using standardization techniques common to those skilled in the art. An example of a preferred solution for neutralizing the pH of the hydrolyzed extracellular matrix solution (neutralization buffer) is: 16% w / v sodium hydroxide (NaOH), 3.7% w / v sodium bicarbonate (NaHCO), and 4.8% w / v HEPES, mixed with the acidic matrix, for example, in the ratio 8 (acidic matrix): 1 (neutralization buffer): 1 (DMEM (Dulbecco's Modified Eagle's Medium) 10X). Alternatively, the pH of the hydrolyzed extracellular matrix solution can be neutralized by dialysis.This is a well-known methodology in this technical field for this purpose, and adjustments can be made by a skilled artisan without undue experimentation. Briefly, the hydrolyzed solution is placed in a dialysis bag with appropriate pores large enough to pass salts and water, but not proteins. By changing the water bath in which the bag is inserted, the pH is adjusted to the desired neutral point. Preferably, according to this step of the present invention, neutralization is performed with a sodium hydroxide solution (with buffer) or dialysate. In the context of the present invention, preferably, and regardless of the technique, the pH of the neutralized solution is 6.8 to 8.0, preferably 7.0 to 7.4.

[0132] Still in the case of the processes for producing a tissue-specific hydrogel of the present invention, when applicable, after proceeding with the lyophilization of the hydrolyzed extracellular matrix solution, using known techniques already reported in the state of the art, the resolubilization step is followed with an aqueous solution, the pH of which may or may not be adjusted, preferably to approximately 7 to approximately 7.4; preferably, the resolubilization is with an acidic solution, such as with the acids previously mentioned in the context of acid hydrolysis, preferably with 0.5 M acetic acid.After complete solubilization, in the case of using acid, neutralization to the said preferred pH and equilibration of the salts of said solution follow, as per the neutralization and salt equilibration methods previously described, preferably with the neutralization buffer solution reported above (16% w / v NaOH, 3.7% w / v NaHCOs; 4.8% w / v HEPES), in the reported proportion of solubilized matrix, neutralization buffer and 10x concentrated culture medium in the ratio of 8:1:1. Advantageously, this allows obtaining a final powdered product with a longer shelf life, as well as allowing working with solutions of varying concentrations from resolubilization in mass / volume ratios of interest.

[0133] It is worth noting that, when one chooses, between steps (c) and (d), to lyophilize the hydrolyzed extracellular matrix solution, resolubilize it with an acidic solution, neutralize and balance the salts, the neutralization of step (c) is preferably carried out with a basic solution, preferably a solution comprising sodium hydroxide and / or sodium bicarbonate, without buffer.

[0134] It is also worth noting that, depending on the intended use, the components and / or the extracellular matrix and / or hydrogel of the present invention may be sterilized entirely optionally. This can be accomplished in different ways and at different times, and is within the knowledge of one skilled in the art in the field of the present invention. The present invention further relates to a process for producing a product derived from the tissue-specific extracellular matrix solution, which comprises subjecting the tissue-specific extracellular matrix solution produced by the enzyme-free process of the present invention to one or more of the following chemical modifications:

[0135] (i) introduce acrylate derivatives (such as methacrylate);

[0136] (ii) introduce alkenes, for thiol-ene chemistry (such as thiol-norbornene);

[0137] (iii) introduce thiols, for thiol-ene chemistry or intermolecular disulfide bridges; and / or

[0138] (iv) introduce other chemical groups for bio-orthogonal reactions (such as aldehyde and hydrazide).

[0139] Preferably, the process further comprises crosslinking the modified tissue-specific extracellular matrix solution for transition to a hydrogel.

[0140] Optionally, the modified extracellular matrix solution or hydrogel derived therefrom may be further processed using the following steps: freeze-drying and pulverizing the material to obtain a fine powder. Optionally, resolubilization may then be performed with an aqueous solution, with the pH adjusted to approximately 7 to 7.4. Resolubilization is preferably performed with an acidic solution, followed by neutralization to the preferred pH and salt equilibration. The protocols and reagents in question are as described herein for equivalent steps in other processes and / or will depend on the specific chemical modification reactions, as per the expertise of a person skilled in the art.

[0141] All reactions are known in the literature and can be used as a basis for the present invention without undue experimentation. In particular, acrylate derivatives can be introduced into the hydrogel or solution through various chemical reactions known to those skilled in the art, such as a methacrylation reaction. To methacrylate the extracellular matrix, in one particular example, the methacrylic anhydride reagent is added dropwise to the hydrolyzed extracellular matrix solution at a rate of 2.5 mL / g of matrix. The reaction occurs under constant stirring for varying times and temperatures, which can affect the resulting degree of functionalization. In a preferred example, the reaction occurs for approximately 48 hours at 4°C to 24°C, preferably at room temperature (approximately 22°C).Finally, the reaction product is dialyzed against deionized water for 5 days at room temperature, and the pH is neutralized using a sodium bicarbonate solution. The material is then frozen, lyophilized, and pulverized. Alternatively, methacrylation can be performed by reacting the hydrolyzed extracellular matrix with excess glycidyl methacrylate in the presence of trimethylamine and tetrabutylammonium bromide. In one example, the reaction solution consists of 150 ml of a mixture of acetone and water (1:3), in which 2.2 ml of triethanolamine, 2.2 ml of glycidyl methacrylate, and 2.2 g of tetrabutylammonium are dissolved. The reaction solution is added to the hydrolyzed matrix at a ratio of 150 ml for every 1 g of matrix and then remains under constant stirring for 5 days at room temperature. After this period, the methacrylated extracellular matrix is ​​precipitated with excess ethanol or acetone, centrifuged, and then resolubilized in water.The product is then dialyzed against deionized water for 2 days, with daily water changes, and finally, lyophilized and pulverized. Alkene groups can be introduced into the hydrogel or solution through various chemical reactions known to those skilled in the art, such as thiol-ene chemistry (such as thiol-norbornene). In particular, for chemical modification of the primary amine groups of the matrix with norbornene, the document Münoz, Z.; Shih, H.; Lin, C.C.; "Gelatin hydrogels formed by orthogonal thiol-norbornene photochemistry for cell encapsulation," 2014, is incorporated by reference. Briefly, in one embodiment, one can, for example, react the soluble hydrolyzed extracellular matrix with a carboxylic anhydride (such as cis-5-norbornene-endo-2,3-dicarboxylic anhydride, CAS 129-64-6).The reagent is added to the soluble matrix at a ratio of 2 g for every 1 g of matrix, the pH is neutralized with sodium hydroxide, and the reaction is carried out for 3 hours at room temperature. At the end of the reaction period, 5x the volume of phosphate-buffered saline (PBS) is added to stop the reaction, and the reaction mixture is centrifuged to remove any undissolved anhydride. Finally, the reaction product is dialyzed against deionized water for 3 days at room temperature, and the pH is neutralized using sodium bicarbonate solution. The material is then frozen, lyophilized, and pulverized.

[0142] Thiol groups can be introduced into the hydrogel or solution through various chemical reactions familiar to those skilled in the art. For example, for the thiolation reaction, the document Petrou, CL et al., “Clickable decellularized extracellular matrix as a new tool for building hybrid-hydrogels to model chronic fibrotic diseases in vitro,” 2020, is incorporated by reference. In one embodiment, the soluble hydrolyzed extracellular matrix is ​​reacted with 2-iminothiolane hydrochloride (Traut's reagent). Initially, the primary amine groups in the extracellular matrix must be quantified, which can be done using the ninhydrin assay. The matrix is ​​then reacted with an excess of Traut's reagent in a 75 molar ratio relative to the primary amine concentration determined in the matrix, in the presence of 2 mM ethylenediaminetetraacetic acid (EDTA) for 2 h at room temperature.After the reaction, the solution is filtered or dialyzed to remove Traut's reagent and finally the material is lyophilized and pulverized.

[0143] Other chemical groups can be introduced into the hydrogel or solution through various chemical reactions known to those skilled in the art, such as bioorthogonal reactions (such as aldehyde and hydrazide insertion), as indicated in Koivisto, J.T. et al., “Mechanically Biomimetic Gelatin-Gellan Gum Hydrogels for 3D Culture of Beating Human Cardiomyocytes,” 2019, incorporated by reference. Particular examples include chemical modification of the extracellular matrix with adipic hydrazide or carbohydrazide. For chemical modification of the matrix with adipic hydrazide, for example, soluble hydrolyzed extracellular matrix can be reacted with this reagent at a ratio of 0.225 M hydrazide per 1 g of matrix. The pH of the reaction mixture is adjusted to neutral using sodium hydroxide and the reaction occurs for 24 hours in the presence of 0.03 M carbodiimide (EDC) and 0.03 M hydroxybenzotriazole (HOBt).Finally, the reaction product is dialyzed against deionized water for 2 days at room temperature, and the pH is neutralized using a sodium bicarbonate solution. The material is then frozen, lyophilized, and pulverized.

[0144] The introduction of these chemical groups into the hydrogel or solution of the present invention is useful because it allows the mechanical properties and degradation rate of the hydrogels obtained after gelation of the chemically modified extracellular matrix to be manipulated and adjusted according to the needs of different applications, as it opens the possibility of using different strategies for reinforcing the hydrogel structure, or crosslinking techniques. In other words, in addition to thermal crosslinking, which can act to reinforce the product, the modifications allow for the manipulation of these mechanical properties and control of degradability through strong chemical reactions, which can be mediated by light irradiation, for example (in the case of methacrylation) or by combination with other crosslinking agents (as in the case of thiol-ene chemistry). Depending on the degree of crosslinking (e.g., by adding more or fewer chemical groups, applying more or less light, etc.), the hydrogels can be characterized by their high degree of crosslinking.) it is possible, advantageously, to obtain products with different properties of interest.

[0145] Thus, the present invention also relates to a product derived from the tissue-specific extracellular matrix solution, wherein the product is the tissue-specific solution produced by the enzyme-free process of the present invention, or the tissue-specific hydrogel or produced by the enzyme-free processes of the present invention, comprising one or more of said chemical modifications.

[0146] Furthermore, the present invention relates to a process for producing a tissue-specific soluble powder, as well as to the tissue-specific soluble powder produced by the process, which comprises subjecting the tissue-specific neutral extracellular matrix solution produced by the process disclosed herein, or the tissue-specific hydrogel disclosed herein, or produced by the enzyme-free processes disclosed herein, or the product derived from the tissue-specific extracellular matrix solution disclosed herein, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein, to lyophilization and pulverization. Lyophilization and pulverization, as already mentioned, can be carried out by one of the various prior art methodologies, some of which are already mentioned herein. Preferably, the tissue-specific soluble powder is obtained by milling.

[0147] The present invention further relates to a process for producing a tissue-specific membrane, as well as to the tissue-specific membrane produced by the process, which comprises subjecting the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined herein, or the tissue-specific hydrogel disclosed herein or produced by the enzyme-free processes disclosed herein, or the product derived from the tissue-specific extracellular matrix solution disclosed herein, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein, to dehydration. The dehydration technique is known and widely used in the prior art for this purpose.Commonly used techniques for dehydrating hydrogels include freeze-drying and air-drying, the variables of which, such as time, temperature, etc., can be easily determined by someone skilled in the art of the present invention. Preferably, the freeze-drying dehydration technique involves freezing the hydrogel (ideally below -40°C); placing it in the freeze-drying chamber; cooling the freeze-drying chamber below -40°C; exposing the frozen material to a vacuum; waiting for hours to days (depending on the freeze-dryer's power, sample size, etc.); turning off the cooling and vacuum, and removing the freeze-dried sample from the chamber. The air-drying technique, preferably, involves allowing it to air dry. Variables such as temperature and humidity can be adjusted to better control the process, such as by placing the material in a dry incubator at an elevated temperature (around 40°C).

[0148] The present invention further relates to a process for providing bioactive compounds for regenerating tissue using the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process for producing said solution disclosed herein, the tissue-specific hydrogel disclosed herein, or produced by the enzyme-free processes disclosed herein, or the product derived from the tissue-specific extracellular matrix solution disclosed herein, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein, comprising (a) loading the solution, the hydrogel, or product derived from the solution with the bioactive compound(s); and (b) applying the solution, the hydrogel, or product derived from the solution loaded with the bioactive compound(s) onto or within the target tissue to be regenerated.When loading the tissue-specific neutral extracellular matrix solution with the bioactive compound(s), it can be applied directly onto or within the target tissue to be regenerated so that it crosslinks with the tissue itself. Any prior art loading techniques can be used and are within the skill of the art, but are not of particular relevance to the present invention. For example, preferably, the bioactive compounds can be resuspended in the hydrogel, resulting in a hydrogel dilution of approximately 10%.

[0149] The present invention further relates to a process for providing bioactive compounds for regenerating tissue using a tissue-specific membrane disclosed herein, or produced by the process for producing a tissue-specific membrane disclosed herein, comprising (a) loading the tissue-specific neutral extracellular matrix solution, the tissue-specific hydrogel, or the product derived from the tissue-specific extracellular matrix solution with the bioactive compound(s); (b) dehydrating the solution, the hydrogel, or the product derived from the extracellular matrix solution loaded with the bioactive compound(s) to produce a membrane; and (c) applying the membrane loaded with the bioactive compound(s) onto the target tissue to be regenerated; wherein steps (a) and (b) may occur in any order, i.e., said process may occur either as (a)-(b)-(c) or as (b)-(a)-(c).

[0150] Furthermore, the present invention also relates to an in vitro process for delivering bioactive compounds via the tissue-specific hydrogel disclosed herein, or produced by the enzyme-free processes disclosed herein, or in the product derived from the tissue-specific extracellular matrix solution disclosed herein or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein, wherein the hydrogel or the product derived from the solution is used for tissue regeneration, comprising loading the hydrogel or the product derived from the solution with the bioactive compound(s). Preferably, this latter process further comprises dehydrating the hydrogel or the product derived from the solution loaded with the bioactive compound(s) to produce a membrane.Loading and dehydration techniques have already been discussed and can also be used to carry out this process. It is worth noting that the bioactive compound(s) (one or more bioactive compounds) are preferably selected from the group specified previously in this document and can be used alone or in any combination, depending on the intended use.

[0151] The present invention also relates to the use of the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined herein, or of the tissue-specific hydrogel disclosed herein or produced by the enzyme-free processes disclosed herein, or of the product derived from the tissue-specific extracellular matrix solution disclosed herein or produced by the process to produce a product derived from the solution disclosed herein for the manufacture of a product. Preferably, the product is for tissue regeneration, and in which the tissue-specific neutral extracellular matrix solution, the hydrogel, or the product derived from the solution can be loaded with one or more bioactive compounds as previously described herein, alone or in any combination, depending on the use of interest, by usual loading techniques already described.The product according to the present invention may be a tissue-specific soluble powder, a tissue-specific membrane, a carrier for loading bioactive compounds, such as for tissue regeneration, an additive ingredient for cell culture media, a bioink for 3D bioprinting, and a surface coating solution for cell culture. The products are generally produced according to the processes of the present invention.

[0152] The present invention also relates to the use of the tissue-specific neutral extracellular matrix solution produced by the process defined herein, or of the tissue-specific hydrogel disclosed herein or produced by the enzyme-free processes disclosed herein, or of the product derived from the tissue-specific extracellular matrix solution disclosed herein or produced by the process to produce a product derived from the tissue-specific extracellular matrix solution disclosed herein as a tissue-specific soluble powder, as a tissue-specific membrane, as a loading support for bioactive compounds, such as for regenerating tissue and cultivating cells and / or cell aggregates, as an additive ingredient for cell culture medium, as a bioink for 3D bioprinting, and as a surface coating solution for cell culture.

[0153] The present invention also relates to the use of the tissue-specific extracellular matrix solution produced by the enzyme-free process disclosed by this document for the manufacture of derivative products, in which the products comprise the solution with one or more of the following chemical modifications:

[0154] (i) addition of acrylate derivatives (such as methacrylation);

[0155] (ii) addition of alkenes for thiol-ene chemistry (such as thiol-norbornene);

[0156] (iii) addition of thiols for thiol-ene chemistry or intermolecular disulfide bridges; and / or

[0157] (iv) addition of other chemical groups for bioorthogonal reactions (such as aldehyde and hydrazide). Methods for carrying out such modifications have been exemplified above. The present invention also relates to an additive ingredient for cell culture medium, comprising the tissue-specific soluble powder disclosed herein. Once the powder is diluted in the cell culture medium, the cells become exposed to tissue-specific proteins during culture.

[0158] The present invention further relates to a process for culturing cells within the tissue-specific hydrogel disclosed herein or produced by the enzyme-free processes disclosed herein, or the product derived from the tissue-specific extracellular matrix solution disclosed herein or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein, comprising (a) loading the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined herein or the product derived from the tissue-specific extracellular matrix solution with cells at a cell concentration between about 1 x 10 3 and about 1 x 10 10 cells / mL. Preferably, the cell concentration is between about 1 x 10 4 and about 1 x 10 9cells / mL, more preferably between about 1 x 10 5 and about 1 x 10 8 cells / mL. Another step of the process of the present invention is (b) crosslinking the tissue-specific neutral extracellular matrix solution or the product derived from the tissue-specific extracellular matrix solution with the cells to produce a crosslinked 3D construct. Yet another step of the process of the present invention is (c) providing the cells with growth conditions that allow them to populate the crosslinked 3D construct to form a mature, functional tissue. Suitable growth conditions include the specific culture conditions of each tissue or organ and are known in the prior art and / or can be readily obtained from existing literature and scientific publications.

[0159] Similar reasoning can be carried out for another process of the present invention, which relates to a process of culturing cell aggregates within the tissue-specific hydrogel disclosed herein or produced by the enzyme-free processes disclosed herein, or the product derived from the tissue-specific extracellular matrix solution disclosed herein or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein, comprising (a) loading the tissue-specific neutral extracellular matrix solution produced by the enzyme-free process defined herein or the product derived from the tissue-specific extracellular matrix solution with the cell aggregates, such as spheroids,organoids and cell monolayers. Another step of the process of the present invention comprises (b) crosslinking the tissue-specific neutral extracellular matrix solution or the product derived from the tissue-specific extracellular matrix solution with the cell aggregates to produce a crosslinked 3D construct. Yet another step of the process of the present invention is (c) providing the cell aggregates with growth or maintenance conditions. Suitable growth conditions include the particular culture conditions of each tissue or organ, as already discussed. It is worth noting that, in both the case of the process for cultivating cells and in the case of the process for cultivating cell aggregates, according to the present invention, one can optionally proceed with the step of incorporating biomaterials and / or bioactive compounds before step (a),or between steps (a) and (b). The present invention further relates to a process for bioprinting 3D bioinks comprising cells or cell aggregates within the tissue-specific hydrogel disclosed herein or produced by the enzyme-free processes disclosed herein, or the product derived from the tissue-specific extracellular matrix solution disclosed herein or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein, or the tissue-specific extracellular matrix solution produced by the enzyme-free process for producing a tissue-specific extracellular matrix solution disclosed herein, comprising (a) loading cells or cell aggregates into the hydrogel, or into the product derived from the tissue-specific extracellular matrix solution, or into the tissue-specific neutral extracellular matrix solution,or in combinations of such hydrogels or products or solutions with other biomaterials. In this context, the term "other biomaterials" refers to biological materials generally used for 3D bioprinting, such as natural biomaterials and synthetic biomaterials. Natural biomaterials include, but are not limited to, those made from fibrin, collagen, elastin, gelatin, polypeptides, hyaluronic acid, polysaccharides (including alginate, agarose, chitosan, pectin, and nanocellulose), and modified natural polymers, as well as mixtures or compositions containing these. Synthetic biomaterials include those made from polyethylene glycol, polyacrylic acid, polyvinyl alcohol, polyacrylic acid, poly(methyl methacrylate), polymethacrylic acid, polyacrylamide, polyvinylpyrrolidone, polyurethane, poly(hydroxyethyl methacrylate), poly(N-isopropyl acrylamide) and polyamide,their mixtures or compositions containing them. Other steps of the process of the present invention comprise (b) loading the mixture described in item (a) into the printing chamber of a 3D bioprinter and (c) performing the 3D printing steps, according to the mechanism of action of the 3D bioprinter, which, obviously, may vary depending on the equipment in question. In this context, it should be noted that any 3D bioprinter can be used for the process of the present invention. Still, another step of the process of the present invention comprises (c) cross-linking to stabilize the 3D bioprinted construct. Furthermore, the process of the present invention comprises step (e) of providing the cells with growth conditions so as to allow them to populate the 3D bioprinted construct to form a mature functional tissue. Said growth conditions may vary in each case, and a person skilled in the art, based on this document and / or knowledge of the prior art,would be able to obtain the mentioned population without undue experimentation.

[0160] The present invention also relates to a process for 3D bioprinting from a tissue-specific extracellular matrix solution, comprising producing a tissue-specific extracellular matrix solution by means of steps (a) and (b) of the enzyme-free process disclosed by this document; (c) loading the hydrolyzed extracellular matrix solution from step (b) into the printing chamber of a 3D bioprinter; (d) performing the 3D printing steps in accordance with the mechanism of action of the 3D bioprinter; and (e) crosslinking to stabilize the bioprinted 3D construct. Examples of techniques for the respective steps have been previously described in this document. Preferably, between steps (b) and (c), the step of neutralizing the pH of the hydrolyzed extracellular matrix solution from step (b) is carried out to obtain a tissue-specific neutral extracellular matrix solution, in accordance with the neutralization techniques mentioned above.Alternatively, one can proceed with the pH neutralization of the hydrolyzed extracellular matrix solution during or after the bioprinting of step (d) or after performing the crosslinking step to stabilize the bioprinted 3D construct of step (e). In any case, preferably, between steps (b) and (c), more preferably after the pH neutralization of the hydrolyzed extracellular matrix solution of step (b), if present, one proceeds with the step of incorporation of biomaterials and / or bioactive compounds.

[0161] According to the 3D bioprinting processes (process for bioprinting 3D bioinks and process for 3D bioprinting from an enzyme-free, tissue-specific extracellular matrix solution), the 3D bioprinter's printing chamber preferably comprises a syringe, a Petri dish, a flask, or another 3D bioprinting chamber. Furthermore, the 3D bioprinter can be of any type, such as an extrusion-based bioprinter, a stereolithography-based bioprinter, an inkjet-based bioprinter, a laser-based bioprinter, a tomography-based bioprinter, an acoustic-based bioprinter, or an electrospinning-based bioprinter.Furthermore, according to the 3D bioprinting processes of the present invention, crosslinking preferably comprises one or more of physical crosslinking, such as by changing temperature and / or pH, and adding ions to promote ionic interaction; and chemical crosslinking, such as a reaction to obtain covalent bonds, such as by exposure to light, such as visible light, ultraviolet light and infrared light.

[0162] Finally, the present invention relates to a kit comprising the tissue-specific extracellular matrix solution produced by the enzyme-free process for producing a tissue-specific extracellular matrix solution disclosed herein, or the tissue-specific soluble powder disclosed herein, or produced by the process for producing said powder, or a product derived from the tissue-specific extracellular matrix solution disclosed herein, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution disclosed herein. Preferably, the kit comprises a basic solution together with a buffer solution. Preferably, the basic solution together with the buffer solution is 16% w / v sodium hydroxide (NaOH), 3.7% w / v sodium bicarbonate (NaHCO), 4.8% w / v HEPES, and 10x concentrated culture medium.

[0163] The preferred characteristics and embodiments of the processes and products of the present invention, as described above, can also be envisaged for the present uses, and vice versa.

[0164] The technical characteristics of the processes of the present invention can be better understood based on the examples below, and should therefore not be interpreted in a limiting manner.

[0165] Example 1

[0166] Enzyme-free process to produce tissue-specific hydrogels

[0167] Decellularization of porcine heart tissue was initially achieved by dissection to separate the aortic tissue from the other cardiac tissues. The native tissue was then subjected to a 24-hour freezing cycle at -20°C and thawing at room temperature for 24 hours. The tissue was then ground in a semi-industrial grinder until the tissue fragments were smaller than 2 mm, followed by five washes with water, and incubation of the resuspended material with deionized water at room temperature for 3 hours.After this period, the supernatant liquid was discarded, followed by resuspension of the tissue and incubation at room temperature for 3 hours, this time with water saturated in sodium chloride, followed by 3 washes with water, and incubation of the material with sodium lauryl ether sulfate (SLES) or sodium dodecyl sulfate (SDS) at 1% for 24 hours; after, the tissue was subjected to another 5 washes with water and incubation with Triton X-100 at 1% for 24 hours, followed by 5 new washes with water.

[0168] After decellularization, the decellularized extracellular matrix was freeze-dried at -45 °C for 24 hours and pulverized with a Willey-type grinder.

[0169] Next, the isolated extracellular matrix powder was hydrolyzed at 10 mg / mL in 0.5 M acetic acid for 1 week at 4 °C under constant agitation, in the absence of proteolytic enzymes. The hydrolyzed decellularized extracellular matrix solution was then centrifuged at 15,000 xg for 10 min to remove unhydrolyzed particles; the supernatant was separated and the sedimented material was discarded.

[0170] Subsequent neutralization of the supernatant was performed using a neutralizing buffer solution containing 2.2% sodium bicarbonate and 15% sodium hydroxide in phosphate-saline buffer, followed by incubation of the neutralized decellularized extracellular matrix solution at 37 °C for 1 hour in an incubator with CO2 and humidity control to transition to a hydrogel.

[0171] Example 2

[0172] Enzyme-free process to produce tissue-specific hydrogels

[0173] Tissue decellularization was performed according to the methodology described in Example 1. Next, this was followed directly by hydrolysis of the isolated extracellular matrix powder at 10 mg / mL in 0.5 M acetic acid for 1 week at 4 °C under constant agitation, in the absence of proteolytic enzymes. Afterwards, the pH neutralization of the hydrolyzed extracellular matrix solution was obtained by adding a basic solution (neutralization buffer) with 16% w / v NaOH, 3.7% w / v NaHCC , 4.8% w / v HEPES, mixed with the acidic matrix in a ratio of 8 (acidic matrix): 1 (neutralization buffer): 1 (DMEM 10x Sigma D2429), followed by incubation of the neutralized decellularized extracellular matrix solution at 37 °C for 1 hour in an incubator with CO2 and humidity control for transition to a hydrogel.

[0174] Example 3

[0175] Process for producing a tissue-specific extracellular matrix solution-derived product

[0176] The hydrolyzed extracellular matrix solution at 10 mg / mL in 0.5 M acetic acid for 1 week at 4 °C under constant stirring, as described in the previous example, was prepared and at the end of the process its pH was adjusted to 8 using 0.1 M sodium hydroxide (NaOH) solution. To carry out the methacrylation reaction of the extracellular matrix, methacrylic anhydride reagent was added dropwise to the pH 8 solution at a proportion of 2.5 mL for each 1 g of extracellular matrix, and then remained under constant stirring for 48 hours at room temperature (approximately 22 °C). At the end of the period, the methacrylated matrix obtained was dialyzed against deionized water for 5 days at room temperature, with daily water changes, to remove unreacted methacrylic acid and anhydride. The pH correction to 7 (neutralization) was performed at the end of dialysis using a 0.1 M sodium bicarbonate (NaHCO) solution.The neutralized solution was then frozen, lyophilized, and pulverized. The resulting material was sterilized by exposure to ethylene oxide. The methacrylated extracellular matrix was then resolubilized in an acidic solution (0.5 M acetic acid) at concentrations between 1% and 3%. After complete solubilization, the solution was neutralized and the salts were equilibrated using a neutralization buffer solution (16% w / v NaOH, 3.7% w / v NaHCO3; 4.8% w / v HEPES). To achieve this, the solubilized methacrylated extracellular matrix was mixed with the neutralization buffer and 10x concentrated culture medium in a ratio of 8:1:1, respectively. The product derived from the tissue-specific extracellular matrix solution, obtained by the addition of acrylate groups through methacrylation as described above, is photocrosslinkable when combined with a photoinitiator.

Claims

Claims 1. An enzyme-free process for producing a tissue-specific extracellular matrix solution, based on decellularized extracellular matrix, characterized by comprising: (a) to decellularize a tissue or organ in order to obtain the isolated extracellular matrix; and (b) hydrolyze the isolated extracellular matrix in an acidic environment, in the absence of proteolytic enzymes, optionally followed by purification of the solution.

2. Process according to claim 1, characterized in that after step (b), proceeding with step (c) to neutralize the pH of the hydrolyzed extracellular matrix solution from step (b) to obtain a neutral tissue-specific extracellular matrix solution.

3. Process according to claim 2, characterized by, after step (c), proceeding with step (d) of crosslinking the tissue-specific neutral extracellular matrix solution for transition to a hydrogen.

4. Enzyme-free process for producing a tissue-specific hydrogel based on a decellularized extracellular matrix, characterized by comprising: producing a tissue-specific extracellular matrix solution by means of steps (a) and (b) of the enzyme-free process as defined in claim 1; (c) neutralize the pH of the hydrolyzed tissue-specific extracellular matrix solution from step (b) to obtain a neutral tissue-specific extracellular matrix solution; and (d) to crosslink the tissue-specific neutral extracellular matrix solution for transition to a hydrogel.

5. Process according to any one of claims 1 to 4, characterized in that, between steps (a) and (b), proceed with the step of lyophilizing the isolated extracellular matrix and pulverizing the lyophilized material to obtain a fine powder of isolated extracellular matrix.

6. Process, according to any one of claims 3 to 5, characterized by, between steps (c) and (d), proceeding with the steps of lyophilizing the hydrolyzed extracellular matrix solution, resolubilizing with an aqueous solution, with or without pH adjustment; preferably, resolubilization is with an acidic solution, followed by neutralization and equilibration of the salts.

7. Process, according to any one of claims 1 to 6, characterized in that decellularization is carried out with at least one detergent selected from the group consisting of Triton X-100, sodium dodecyl sulfate (SDS), sodium lauryl ether sulfate (SLES), sodium cholate, sodium deoxycholate, Sulfobetaine-10 (SB-10), Sulfobetaine-16 (SB-16), Triton X-200, 3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate (CHAPS), sodium lauroyl sarcosinate (sarcosyl), n-dodecyl-BD-maltoside (DDM), digitonin, polysorbate 20 and polysorbate 80.

8. A process according to any one of claims 1 to 7, characterized in that hydrolysis in an acidic environment is carried out with an acid selected from the group consisting of acetic acid, hydrochloric acid, citric acid, lactic acid and trifluoroacetic acid, preferably acetic acid or hydrochloric acid, more preferably acetic acid.

9. Process, according to any one of claims 2 to 8, characterized in that the neutralization is by dialysis or carried out with a basic solution, preferably a solution comprising sodium hydroxide and / or sodium bicarbonate, optionally in conjunction with a buffer solution comprising one or more of sodium bicarbonate buffer, phosphate-saline buffer, Dulbecco's phosphate-saline buffer, HEPES (4-(2-hydroxyethyl)-1-piperazinoethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid) and MOPS (3-(N-morpholino)propanesulfonic acid).

10. A process according to any one of claims 1 to 9, characterized in that the tissue or organ of origin is selected from the group consisting of adipose tissue, bone tissue, brain, cartilage tissue, colon, kidney, liver, lung, muscle tissue, myocardial tissue, pancreas, skin, spleen, stomach, vascular tissue, dental tissue, glandular tissue, such as the adrenal gland, parathyroid gland, thyroid gland, pituitary gland and salivary gland, bone marrow tissue, tissue of the male reproductive system, such as the testicle, epididymis, prostate, seminal vesicle and vas deferens, tissue of the female reproductive system, such as the vagina, cervix, endometrium, fallopian tube, ovary and placenta, intestine, urinary bladder and eye.

1. Tissue-specific hydrogel, characterized by being produced by enzyme-free processes, as defined in any one of claims 3 to 10.

12. Process for producing a product derived from tissue-specific extracellular matrix solution, characterized by comprising subjecting the tissue-specific extracellular matrix solution, produced by the enzyme-free process as defined in any one of claims 1 to 2, to one or more of the following chemical modifications: (i) introduce acrylate derivatives (such as methacrylation); (ii) introduce alkenes, for thiol-ene chemistry (such as thiol-norbornene); (iii) introduce thiols, for thiol-ene chemistry or intermolecular disulfide bridges; and / or (iv) introduce other chemical groups for bio-orthogonal reactions (such as aldehyde and hydrazide).

13. Process according to claim 12, characterized by further comprising crosslinking the modified tissue-specific extracellular matrix solution for transition to a hydrogel.

14. Product derived from tissue-specific extracellular matrix solution, characterized in that the product is the tissue-specific solution, produced by an enzyme-free process as defined in any one of claims 1, 2, 5 and 7 to 10, or the tissue-specific hydrogel obtained therefrom, as defined in claim 11, or produced by enzyme-free processes as defined in any one of claims 3 to 10, comprising one or more of the following modifications. chemicals: (i) addition of acrylate derivatives (such as methacrylation); (ii) addition of alkenes to thiol-ene chemistry (such as thiol-norbornene); (iii) addition of thiols for thiol-ene chemistry or intermolecular disulfide bridges; and / or (iv) addition of other chemical groups for bio-orthogonal reactions (such as aldehyde and hydrazide).

15. Process for producing a tissue-specific soluble powder, characterized by comprising subjecting the tissue-specific neutral extracellular matrix solution, produced by the enzyme-free process for producing said solution, as defined in any one of claims 2, 5 and 7 to 10, or the tissue-specific hydrogel, as defined in claim 11, or produced by the enzyme-free processes, as defined in any one of claims 3 to 10, or the product derived from the tissue-specific extracellular matrix solution, as defined in claim 14, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13, to lyophilization and pulverization.

16. Tissue-specific soluble powder, characterized by being obtained by lyophilization and pulverization of a tissue-specific neutral extracellular matrix solution, produced by an enzyme-free process to produce the solution, as defined in any one of claims 2, 5 and 7 to 10, or of a tissue-specific hydrogel, as defined in claim 11, or produced by an enzyme-free process, as defined in any one of claims 3 to 10, or of a product derived from a tissue-specific extracellular matrix solution, as defined in claim 14, or produced by a process to produce a product derived from a tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13.

17. Process for producing a tissue-specific membrane, characterized by comprising subjecting the tissue-specific neutral extracellular matrix solution, produced by the enzyme-free process for producing said solution, as defined in any one of claims 2, 5 and 7 to 10, or the tissue-specific hydrogel, as defined in claim 11, or produced by the enzyme-free processes, as defined in any one of claims 3 to 10, or the product derived from the tissue-specific extracellular matrix solution, as defined in claim 14, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13, to dehydration.

18. Tissue-specific membrane, characterized by being obtained by dehydrating a tissue-specific neutral extracellular matrix solution, produced by an enzyme-free process to produce said solution, as defined in any one of claims 2, 5 and 7 to 10, or of a tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or of a product derived from a tissue-specific extracellular matrix solution, as defined in claim 14, or produced by a process to produce a product derived from a tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13.

19. Process for providing bioactive compounds to regenerate tissue, using a tissue-specific neutral extracellular matrix solution, produced by an enzyme-free process to produce said solution, as defined in any one of claims 2, 5 and 7 to 10, the tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or the product derived from the tissue-specific extracellular matrix solution, as defined in claim 14, or produced by a process to produce a product derived from the tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13, characterized by comprising: (a) loading the solution, tissue-specific hydrogel or tissue-specific extracellular matrix solution-derived product with the bioactive compound(s); and (b) Apply the solution, hydrogel, or product derived from the extracellular matrix solution loaded with the bioactive compound(s) onto or within the target tissue to be regenerated.

20. Process for providing bioactive compounds to regenerate tissue, using the tissue-specific membrane as defined in claim 18, or produced by the process for producing a tissue-specific membrane as defined in claim 17, characterized by comprising: (a) loading the tissue-specific neutral extracellular matrix solution, tissue-specific hydrogel or tissue-specific extracellular matrix solution-derived product with the bioactive compound(s); (b) dehydrate the solution, hydrogel or product derived from the extracellular matrix solution loaded with the bioactive compound(s) to produce a membrane; and (c) apply the membrane loaded with the bioactive compound(s) onto the target tissue to be regenerated; wherein steps (a) and (b) may occur in any order.

21. In vitro process for delivering bioactive compounds via tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or via tissue-specific extracellular matrix solution-derived product, as defined in claim 14, or produced by the process for producing a tissue-specific extracellular matrix solution-derived product, as defined in any one of claims 12 to 13, wherein the hydrogel or the extracellular matrix solution-derived product is for tissue regeneration, characterized by comprising loading the tissue-specific hydrogel or the tissue-specific extracellular matrix solution-derived product with the bioactive compound(s).

22. Process according to claim 21, characterized by further comprising dehydrating the hydrogel or the product derived from the extracellular matrix solution loaded with the bioactive compound(s) to produce a membrane.

23. Process, according to any one of claims 19 to 22, characterized in that the bioactive compound(s) is / are selected from the group consisting of: - cells, preferably differentiated adult cells and stem cells; preferably wherein the differentiated adult cells are cells derived primarily from endoderm, cells derived primarily from ectoderm and cells derived primarily from mesoderm; and preferably wherein the stem cells are embryonic stem cells, induced pluripotent stem cells and adult stem cells, or any combination thereof; - Factors secreted by cells, preferably selected from the group consisting of growth factors, cytokines, chemokines and microRNAs, or any combination thereof; - Vesicles secreted by cells, preferably selected from the group consisting of exosomes, microvesicles, apoptotic bodies and ectosomes, or any combination thereof; - nucleic acids, preferably selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNAs (rRNA), microRNAs (miRNA), small interfering RNAs (siRNA), piwi-interacting RNAs (piRNA), small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs), extracellular RNAs (exRNAs), small Cajal body-specific RNAs (scaRNAs), long non-coding RNAs (IncRNAs), double-stranded RNAs (dsRNAs) and circular RNAs, or any combination thereof; - medications; - Biological medical products, preferably selected from the group consisting of chimeric antigen receptor T cells (CAR T cells), monoclonal antibodies, fusion proteins, tumor necrosis factor alpha (TNFα), leukocyte surface glycoproteins, adhesion molecules, immunoglobulins, receptor targets and viruses, or any combination thereof; - metallic particles (such as silver nanoparticles), ceramic particles (such as hydroxyapatite), organic particles (such as nanoemulsions and polymeric nanoparticles), lipid particles (such as liposomes) and carbon nanomaterials (such as fullerenes, carbon nanotubes, graphene and graphene oxide), or any combinations thereof; or any combinations thereof.

24. Use of neutral tissue-specific extracellular matrix solution, produced by the enzyme-free process to produce said solution, as defined in any one of claims 2, 5 and 7 to 10, or of tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or of the product derived from the tissue-specific extracellular matrix solution, as defined in claim 14, or produced by the process to produce a product derived from the tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13, characterized in that it is for the manufacture of a product.

25. Use according to claim 24, characterized in that the product is for regenerating tissue, and wherein the tissue-specific neutral extracellular matrix solution, or the tissue-specific hydrogel, or the product derived from the tissue-specific extracellular matrix solution is loaded with one or more bioactive compounds, wherein the one or more bioactive compounds are selected from the group that It consists of cells, cell-secreted factors, cell-secreted vesicles, nucleic acids, drugs, biological medical products, metallic particles (such as silver nanoparticles), ceramic particles (such as hydroxyapatite), organic particles (such as nanoemulsions and polymeric nanoparticles), lipid particles (such as liposomes) and carbon nanomaterials (such as fullerenes, carbon nanotubes, graphene and graphene oxide), or a combination thereof.

26. Use, according to claim 24, characterized in that the product is selected from the group consisting of a tissue-specific soluble powder, a tissue-specific membrane, a loading support for bioactive compounds, such as for regenerating tissue, an additive ingredient for cell culture medium, a bio-ink for 3D bioprinting and a surface coating solution for cell culture.

27. Use of neutral tissue-specific extracellular matrix solution, produced by the enzyme-free process to produce said solution, as defined in any one of claims 2, 5 and 7 to 10, or of tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or of the product derived from the tissue-specific extracellular matrix solution, as defined in claim 14, or produced by the process to produce a product derived from the tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13, characterized in that it is a soluble tissue-specific powder, a tissue-specific membrane, a loading support for bioactive compounds, such as for regenerating tissue and culturing cells and / or cell aggregates, an additive ingredient for cell culture media,as a bio-ink for 3D bioprinting and as a surface coating solution for cell culture.

28. Use of tissue-specific extracellular matrix solution, produced by the enzyme-free process, as defined in any one of claims 1, 2, 5 and 7 to 10, characterized in that it is for the manufacture of derivative products, wherein the products comprise the solution with one or more of the following chemical modifications: (i) addition of acrylate derivatives (such as methacrylation); (ii) addition of alkenes to thiol-ene chemistry (such as thiol-norbornene); (iii) addition of thiols for thiol-ene chemistry or intermolecular disulfide bridges; and / or (iv) addition of other chemical groups for bio-orthogonal reactions (such as aldehyde and hydrazide).

29. Additive ingredient for cell culture medium, characterized by comprising a tissue-specific soluble powder, as defined in claim 16.

30. A process for cultivating cells within tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or from a product derived from tissue-specific extracellular matrix solution, as defined in claim 14, or produced by a process for producing a product derived from tissue-specific extracellular matrix solution, as defined in any one of claims 3 to 10. 12 to 13, characterized by the process of understanding: (a) charging the tissue-specific neutral extracellular matrix solution, produced by the enzyme-free process to produce said solution, as defined in any one of claims 2, 5 and 7 to 10, or the product derived from the tissue-specific extracellular matrix solution with the cells, at a cell concentration between 1 x 10 3 and 1 x 1 O 10 cells / mL; (b) crosslink the tissue-specific neutral extracellular matrix solution or the product derived from the tissue-specific extracellular matrix solution with the cells to produce a crosslinked 3D construct; and (c) provide the cells with growth conditions so that they can populate the 3D reticulated structure to form a mature functional tissue.

31. A process for cultivating cell aggregates within tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or from a product derived from tissue-specific extracellular matrix solution, as defined in claim 14, or produced by a process for producing a product derived from tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13, characterized in that the process comprises: (a) charging the tissue-specific neutral extracellular matrix solution, produced by the enzyme-free process to produce said solution, as defined in any one of claims 2, 5 and 7 to 10, or the product derived from the tissue-specific extracellular matrix solution with cell aggregates, such as spheroids, organoids and cell monolayers; (b) crosslink the tissue-specific neutral extracellular matrix solution or the product derived from the tissue-specific extracellular matrix solution with the cell aggregates to produce a crosslinked 3D construct; and (c) to provide cell aggregates with conditions for growth or maintenance.

32. Process for bioprinting 3D bioinks, comprising cells or cell aggregates within tissue-specific hydrogel, as defined in claim 11, or produced by enzyme-free processes, as defined in any one of claims 3 to 10, or from the product derived from tissue-specific extracellular matrix solution, as defined in claim 14, or produced by the process for producing a product derived from tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13, or from tissue-specific extracellular matrix solution, produced by the enzyme-free process for producing a tissue-specific extracellular matrix solution, as defined in any one of claims 2 and 7 to 10, characterized in that the process comprises: (a) to load cells or cell aggregates onto tissue-specific hydrogel or tissue-specific extracellular matrix solution-derived product, or tissue-specific neutral extracellular matrix solution, or combinations of such hydrogels or products or solutions with other biomaterials; (b) load the mixture described in item (a) into the printing chamber of a 3D bioprinter; (c) execute the 3D printing steps, according to the bioprinter's mechanism of action 3D; (d) reticular structure to stabilize the bioprinted 3D construction; and (e) provide the cells with growth conditions so that they can populate the bioprinted 3D construct to form a mature functional tissue.

33. Process for 3D bioprinting, from a tissue-specific extracellular matrix solution, characterized by comprising: producing a tissue-specific extracellular matrix solution by means of steps (a) and (b) of the enzyme-free process, as defined in any one of claims 1, 5, 7, 8 and 10; (c) load the hydrolyzed extracellular matrix solution from step (b) into the printing chamber of a 3D bioprinter; (d) execute the 3D printing steps, according to the mechanism of action of the 3D bioprinter; and (e) reticular to stabilize the bioprinted 3D construction.

34. Process according to claim 33, characterized in that, between steps (b) and (c), proceeding with the step of neutralizing the pH of the hydrolyzed extracellular matrix solution from step (b) to obtain a tissue-specific neutral extracellular matrix solution.

35. Process, according to claim 33, characterized by proceeding with the step of neutralizing the pH of the hydrolyzed extracellular matrix solution during or after bioprinting in step (d) or after crosslinking to stabilize the bioprinted 3D construct in step (e).

36. Process, according to any one of claims 33 to 35, characterized in that, between steps (b) and (c), it proceeds with the step of incorporating biomaterials and / or bioactive compounds.

37. Process, according to any one of claims 32 to 36, characterized in that the 3D bioprinter printing chamber comprises a syringe, a Petri dish, a flask or other 3D bioprinting chamber.

38. Process, according to any one of claims 32 to 37, characterized in that the 3D bioprinter is an extrusion-based bioprinter, a stereolithography-based bioprinter, an inkjet-based bioprinter, a laser-based bioprinter, a tomography-based bioprinter, an acoustics-based bioprinter, or an electrospinning-based bioprinter.

39. A process according to any one of claims 3, 4 to 10, 13, 30 to 32 and 38, characterized in that the crosslinking preferably comprises one or more of the following: physical crosslinking, such as by altering temperature and / or pH, and adding ions to promote ionic interaction; and chemical crosslinking, such as reactions to obtain covalent bonds, such as by exposure to light, such as visible light, ultraviolet light and infrared light.

40. Kit, characterized by comprising the tissue-specific extracellular matrix solution, produced by the enzyme-free process, as defined in claim 1, or the tissue-specific soluble powder, as defined in claim 16, or produced by the process for producing said powder, as defined in claim 15, or a product derived from the tissue-specific extracellular matrix solution, as defined in claim 14, or produced by the process for producing a product derived from the tissue-specific extracellular matrix solution, as defined in any one of claims 12 to 13.

Citation Information

Patent Citations

  • METHOD FOR PREPARING DETERGENT-FREE DECELLULARIZED EXTRACELLULAR MATRIX, DETERGENT-FREE DECELLULARIZED ECM, METHOD FOR PREPARING A PRIMARY BIOINK, PRIMARY BIOINK, METHOD FOR PREPARING A VASCULAR BIOINK, VASCULAR BIOINK, THREE-DIMENSIONAL STRUCTURE, AND, METHOD FOR PREPARING A THREE-DIMENSIONAL STRUCTURE

    BR112022001029A2

  • Bio-ink composition for the three-dimensional printing and process for preparing the same

    KR1020180125776A

  • Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products

    US20180127719A1

  • Preparation and applications of modified cellulose nanofibrils with extracellular matrix components as 3D bioprinting bioinks to control cellular fate processes such as adhesion, proliferation and differentiation

    US20190209738A1